drugset

drugset / Trial / NCT04766177

Role of Bumetanide in Treatment of Autism

NCT04766177 ↗

Phase 3 Recruiting 80 enrolled Tanta University

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Role of bumetanide in Autism

Timeline

Start: 2021-01-01
Primary completion: 2030-12-01
Completion: 2030-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bumetanide	Small molecule	0.5 mg	—

Indications